AR042450A1 - Indazolilpirrolotriazinas modificadas c-6 - Google Patents

Indazolilpirrolotriazinas modificadas c-6

Info

Publication number
AR042450A1
AR042450A1 ARP030104592A ARP030104592A AR042450A1 AR 042450 A1 AR042450 A1 AR 042450A1 AR P030104592 A ARP030104592 A AR P030104592A AR P030104592 A ARP030104592 A AR P030104592A AR 042450 A1 AR042450 A1 AR 042450A1
Authority
AR
Argentina
Prior art keywords
substituted
heterocycle
aryl
alkyl
group
Prior art date
Application number
ARP030104592A
Other languages
English (en)
Inventor
G D Vite
A V Gavai
B E Fink
H Mastalerz
J F Kadow
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR042450A1 publication Critical patent/AR042450A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente proporciona compuestos de la fórmula (1), en donde: R se selecciona del grupo que consiste de arilo, arilo sustituido, heterociclo, y heterociclo sustituido; R1 se selecciona del grupo que consiste de alquilo y alquilo sustituido; R2 se selecciona del grupo que consiste de hidrógeno, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, aralquilo, heterociclo, y heterociclo sustituido; o, R2 puede estar ausente; X se selecciona del grupo que consiste de un enlace, O, S, C(R3)2, C(R3)3, NR3; y N(R3)2; R3 se selecciona independientemente del grupo que consiste de hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, aralquilo, heterociclo, y heterociclo sustituido y sales, profármacos, enantiómeros, diastereómeros, y solvatos farmacéuticamente aceptables del mismo. Los compuestos de la fórmula (1) inhiben la actividad de la tirosina cinasa de los receptores del factor de crecimiento tales como HER1, HER2 y HER4 por lo que son útiles como agentes antiproliferativos para cáncer, psicosis y artritis reumatoidea. Estos compuestos también son útiles para el tratamiento de otras enfermedades asociadas con las trayectorias de transducción de senal, que operan a través de los receptores del factor de crecimiento. Composición farmacéutica que comprende los compuestos de la fórmula (1) junto a un portador farmacológicamente aceptable. Reivindicación 1: Un compuestos de la fórmula (1), en donde: R se selecciona del grupo que consiste de arilo, arilo sustituido, heterociclo, y heterociclo sustituido; R1 se selecciona del grupo que consiste de alquilo y alquilo sustituido; R2 se selecciona del grupo que consiste de hidrógeno, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, aralquilo, heterociclo, y heterociclo sustituido; o, R2 puede estar ausente; X se selecciona del grupo que consiste de un enlace, O, S, C(R3)2, C(R3)3, NR3; y N(R3)2; R3 se selecciona independientemente del grupo que consiste de hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, aralquilo, heterociclo, y heterociclo sustituido y sales, profármacos, enantiómeros, diastereómeros, y solvatos farmacéuticamente aceptables del mismo.
ARP030104592A 2002-12-13 2003-12-12 Indazolilpirrolotriazinas modificadas c-6 AR042450A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43319002P 2002-12-13 2002-12-13

Publications (1)

Publication Number Publication Date
AR042450A1 true AR042450A1 (es) 2005-06-22

Family

ID=32595133

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104592A AR042450A1 (es) 2002-12-13 2003-12-12 Indazolilpirrolotriazinas modificadas c-6

Country Status (27)

Country Link
US (2) US6916815B2 (es)
EP (1) EP1569937B1 (es)
JP (1) JP4511367B2 (es)
KR (1) KR101073801B1 (es)
CN (2) CN1726216A (es)
AR (1) AR042450A1 (es)
AT (1) ATE534648T1 (es)
AU (1) AU2003300877B2 (es)
BR (1) BR0316755A (es)
CA (1) CA2509650C (es)
CO (1) CO5570660A2 (es)
DK (1) DK1569937T3 (es)
ES (1) ES2374393T3 (es)
HR (1) HRP20050535A2 (es)
IS (1) IS7890A (es)
MX (1) MXPA05006164A (es)
NO (1) NO20052733L (es)
NZ (1) NZ540338A (es)
PE (1) PE20040805A1 (es)
PL (1) PL377517A1 (es)
PT (1) PT1569937E (es)
RS (1) RS20050441A (es)
RU (1) RU2356903C2 (es)
TW (1) TW200420565A (es)
UA (1) UA80591C2 (es)
WO (1) WO2004054514A2 (es)
ZA (1) ZA200504507B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
WO2003091229A1 (en) 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
WO2003090912A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
CN102532120A (zh) 2002-08-23 2012-07-04 索隆-基特林癌症研究协会 埃坡霉素(epothilone)，合成埃坡霉素的中间体，其类似物及其用途
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
PL378121A1 (pl) 2003-02-05 2006-03-06 Bristol-Myers Squibb Company Sposób wytwarzania pirolotriazynowych inhibitorów kinazy
EP2641611A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en) * 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
US7102002B2 (en) * 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7253167B2 (en) * 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
TW200600513A (en) * 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7102003B2 (en) * 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en) 2004-08-12 2006-06-16 Bristol Myers Squibb Co Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
AU2005294347A1 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
US7151176B2 (en) * 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
DE602006020032D1 (de) 2005-04-18 2011-03-24 Novo Nordisk As Il-21-varianten
US7405213B2 (en) * 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7402582B2 (en) * 2005-07-01 2008-07-22 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8063208B2 (en) 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
KR20080107408A (ko) 2006-03-07 2008-12-10 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물
CN101553501A (zh) 2006-10-26 2009-10-07 诺沃-诺迪斯克有限公司 Il-21变种
WO2008074863A1 (en) * 2006-12-21 2008-06-26 Novo Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
US20090083483A1 (en) * 2007-09-24 2009-03-26 International Business Machines Corporation Power Conservation In A RAID Array
US8166326B2 (en) * 2007-11-08 2012-04-24 International Business Machines Corporation Managing power consumption in a computer
US20090132842A1 (en) * 2007-11-15 2009-05-21 International Business Machines Corporation Managing Computer Power Consumption In A Computer Equipment Rack
US8041521B2 (en) * 2007-11-28 2011-10-18 International Business Machines Corporation Estimating power consumption of computing components configured in a computing system
MX2010010949A (es) 2008-04-04 2011-02-22 Gilead Sciences Inc Derivados de triazolopiridinona para utilizarse como inhibidores de desaturasa de estearoilo coa.
EP2274308A1 (en) * 2008-04-04 2011-01-19 Gilead Sciences, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
US20110086850A1 (en) * 2008-04-11 2011-04-14 Board Of Regents, The University Of Texas System Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy
US8103884B2 (en) 2008-06-25 2012-01-24 International Business Machines Corporation Managing power consumption of a computer
US8041976B2 (en) * 2008-10-01 2011-10-18 International Business Machines Corporation Power management for clusters of computers
US8514215B2 (en) * 2008-11-12 2013-08-20 International Business Machines Corporation Dynamically managing power consumption of a computer with graphics adapter configurations
ES2539620T3 (es) 2008-12-19 2015-07-02 Cephalon, Inc. Pirrolotriazina como inhibidor de ALK y de JAK2
MX2011009413A (es) * 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
CN103450204B (zh) 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
ES2616025T3 (es) * 2013-03-11 2017-06-09 Bristol-Myers Squibb Company Pirrolotriazinas como inhibidores de canales de iones potasio
ES2616026T3 (es) * 2013-03-11 2017-06-09 Bristol-Myers Squibb Company Pirrolopiridazinas como inhibidores de canales de iones potasio
WO2015081783A1 (zh) * 2013-12-06 2015-06-11 江苏奥赛康药业股份有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
CN111533708B (zh) * 2020-06-12 2021-03-16 上海馨远医药科技有限公司 一种手性n-叔丁氧羰基吗啉-3-羧酸的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908056A (en) * 1986-04-25 1990-03-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
DE69628804T2 (de) 1995-12-08 2003-12-18 Pfizer Inc., New York Substitutierte heterozyclische Derivate als CRF Antagonisten
CZ68199A3 (cs) 1996-08-28 1999-11-17 Pfizer Inc. 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob
JP4649046B2 (ja) * 1999-05-21 2011-03-09 ブリストル−マイヤーズ スクイブ カンパニー キナーゼのピロロトリアジン阻害剤
WO2001014378A1 (fr) 1999-08-23 2001-03-01 Shionogi & Co., Ltd. DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2?
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
ES2259051T3 (es) * 2000-11-17 2006-09-16 Bristol-Myers Squibb Company Procedimientos para el tratamiento de dolencias asociadas a la quinasa p38 y compuestos de pirrolotriacina utiles como inhibidores de quinasa.
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
WO2003090912A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
WO2003091229A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
US7102001B2 (en) * 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine

Also Published As

Publication number Publication date
KR101073801B1 (ko) 2011-10-13
US20050222153A1 (en) 2005-10-06
CA2509650C (en) 2007-10-30
RU2005120650A (ru) 2006-01-20
NZ540338A (en) 2008-05-30
IS7890A (is) 2005-06-10
US20040142931A1 (en) 2004-07-22
US7148220B2 (en) 2006-12-12
EP1569937A2 (en) 2005-09-07
JP4511367B2 (ja) 2010-07-28
CN1726216A (zh) 2006-01-25
TW200420565A (en) 2004-10-16
PL377517A1 (pl) 2006-02-06
MXPA05006164A (es) 2005-08-26
PT1569937E (pt) 2012-01-04
HRP20050535A2 (en) 2005-12-31
ES2374393T3 (es) 2012-02-16
DK1569937T3 (da) 2012-01-02
BR0316755A (pt) 2005-10-25
PE20040805A1 (es) 2004-11-20
KR20050084242A (ko) 2005-08-26
EP1569937B1 (en) 2011-11-23
CA2509650A1 (en) 2004-07-01
CO5570660A2 (es) 2005-10-31
WO2004054514A2 (en) 2004-07-01
UA80591C2 (en) 2007-10-10
ZA200504507B (en) 2006-08-30
RU2356903C2 (ru) 2009-05-27
AU2003300877B2 (en) 2010-02-18
CN101723948A (zh) 2010-06-09
US6916815B2 (en) 2005-07-12
RS20050441A (en) 2007-04-10
ATE534648T1 (de) 2011-12-15
EP1569937A4 (en) 2007-08-08
AU2003300877A1 (en) 2004-07-09
NO20052733D0 (no) 2005-06-07
NO20052733L (no) 2005-07-07
WO2004054514A3 (en) 2004-10-07
JP2006509826A (ja) 2006-03-23

Similar Documents

Publication Publication Date Title
AR042450A1 (es) Indazolilpirrolotriazinas modificadas c-6
AR037368A1 (es) Imidazolilpirrolotriazinas c-5 modificadas y composiciones farmaceuticas que las comprenden
PE20220592A1 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos
BR0314965A (pt) Derivados de 2-oxodiidropiridina n-substituìdos
AR029222A1 (es) Compuesto derivado de amida, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para tratar enfermedades mediadas por la proteinquinasa
ES2150113T3 (es) Derivados de pirazol y procedimientos para la preparacion de los mismos.
UY26086A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
UY26872A1 (es) Derivados de la 4- fenil piridina
UY27225A1 (es) Inhibidores de la rho-quinasa
AR060562A1 (es) Compuestos heterociclicos como antagonistas del receptor il-8. procesos de obtencion y composiciones farmaceuticas.
UY24482A1 (es) Quinoxalinadionas
BRPI0418231A (pt) compostos de pirrolotriazina como inibidores da cinase
UY25344A1 (es) Procedimiento para la preparacion de derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
PT1261602E (pt) Derivados imidazol-2-carboxamida como inibidores de cinase raf
DE60002714D1 (de) Substituierte azaoxindolederivate
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
WO2021222138A1 (en) Compounds for mutant ras protein degradation
RU2005113153A (ru) Новые пиримидинамидные производные и их применение
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
BR112012014807A2 (pt) "compostos adequados para o tratamento de sinucleopatias"
BRPI0411414A (pt) derivados de quinolil amida como antagonistas de cdr-5
KR20200078606A (ko) 항종양제
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
GT200000197A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida.

Legal Events

Date Code Title Description
FB Suspension of granting procedure